CSTL Q1 2025 Earnings — Castle Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CSTLCastle Biosciences, Inc.

$805M

Q1 2025 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$88M+20.6% YoY

Gross Profit

$72M81.4% margin

Operating Income

-$28M-31.7% margin

Net Income

-$26M-29.4% margin

EPS (Diluted)

$-0.90

QoQ Revenue Growth

+1.9%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$11M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$502M

Total Liabilities

$61M

Stockholders' Equity

$440M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$88M	$73M	+20.6%
Gross Profit	$72M	$59M	+21.2%
Operating Income	-$28M	-$5M	-410.5%
Net Income	-$26M	-$3M	-920.0%

Revenue Segments

Dermatologic

$63M100%